The drugs used for Pseudomonas aeruginosa infection are relatively limited, and general oral or intravenous cephalosporin and penicillin treatment are ineffective, mainly using the following drugs for treatment: 1, anti-Pseudomonas aeruginosa penicillin antibiotics: mainly including piperacillin tazobactam; 2, anti-Pseudomonas aeruginosa cephalosporin antibiotics: mainly including ceftazidime, cefoperazone/sulbactam; 3, quinolone antibiotics: including levofloxacin and ciprofloxacin; 4, aminoglycoside antibiotics: including amikacin and etimesine; 5, other β-lactam antibiotics: such as meropenem, imipenem, etc. Pseudomonas aeruginosa is a conditionally pathogenic bacterium, which is usually infected in hospitals, i.e., a common pathogen of nosocomial infections. Pseudomonas aeruginosa infections are mostly seen in immunocompromised people, and are commonly found in patients with more serious conditions such as ICU wards and intensive care units. During the application of antibiotics, drugs should be selected based on the results of drug sensitivity tests, i.e., bacterial culture of the patient’s blood or secretions from the infection site, and antibiotics sensitive to Pseudomonas aeruginosa should be selected. Usually, a combination of 2 or 3 antibiotics is chosen, such as the combination of piperacillin tazobactam, levofloxacin and amikacin, or the combination of meropenem, levofloxacin and amikacin, while the medication should be administered strictly according to the treatment schedule to facilitate good efficacy.